William E. Rote Sells 4,387 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 4,387 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.52, for a total transaction of $50,538.24. Following the transaction, the senior vice president now directly owns 84,455 shares of the company’s stock, valued at approximately $972,921.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Travere Therapeutics Trading Down 0.2 %

NASDAQ TVTX opened at $12.84 on Wednesday. The stock has a market cap of $977.50 million, a P/E ratio of -6.11 and a beta of 0.71. The company’s fifty day simple moving average is $9.39 and its 200-day simple moving average is $7.89. The company has a current ratio of 3.04, a quick ratio of 2.99 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $14.62.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). The firm had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. Equities research analysts predict that Travere Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on TVTX. Piper Sandler boosted their price objective on shares of Travere Therapeutics from $11.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Guggenheim raised Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Monday. Bank of America raised their price objective on Travere Therapeutics from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Barclays lifted their price objective on Travere Therapeutics from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Travere Therapeutics from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its holdings in Travere Therapeutics by 5.6% during the 4th quarter. Russell Investments Group Ltd. now owns 103,012 shares of the company’s stock worth $926,000 after purchasing an additional 5,499 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Travere Therapeutics in the fourth quarter valued at $137,000. Crestline Management LP boosted its stake in Travere Therapeutics by 32.6% during the 4th quarter. Crestline Management LP now owns 81,423 shares of the company’s stock valued at $732,000 after acquiring an additional 20,002 shares during the last quarter. Finepoint Capital LP grew its holdings in Travere Therapeutics by 60.2% during the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after acquiring an additional 539,500 shares in the last quarter. Finally, Rafferty Asset Management LLC increased its position in shares of Travere Therapeutics by 18.6% in the 4th quarter. Rafferty Asset Management LLC now owns 429,161 shares of the company’s stock worth $3,858,000 after purchasing an additional 67,168 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.